Largest Long-Vax Study Sheds Light on Controversial Post-Vaccination Syndrome


While Covid-19 vaccines have been instrumental in saving countless lives, there's a lesser-known narrative that's been unfolding in the background: the saga of Post-Vaccination Syndrome (PVS), also referred to as "Long Vax."

Despite the overshadowing success of the vaccines, it's critical to shine a light on the experiences of those who are grappling with PVS. This is precisely what a Yale University School of Medicine-led research team aimed to do with their LISTEN study.

Their recent findings, shared as a preprint, represent the most extensive PVS study to date, involving 241 participants. The size of this study is a considerable leap from the small case reports and samples of PVS previously reported.

The survey gathered data from a diverse group of participants, primarily women and white, with half under the age of 46. These individuals had not experienced Long Covid and reported a wide array of symptoms, from exercise intolerance and fatigue to neuropathy (nerve pain as a burning or tingling sensation).

A noteworthy aspect of the study is the predominance of mRNA vaccines among the participants, with Pfizer-BioNTech and Moderna being the most common. The onset of symptoms was rapid, often within days of vaccination, and their duration distressingly long – some lasting over a year and a half. This persistence of symptoms encapsulates the essence of "Long Vax."

Beyond the physical symptoms, the study also delves into the profound psychological impact of PVS. A vast majority of participants reported feelings of unease, fear, and anxiety, with many suffering from sleep disturbances and pain that disrupted their daily lives. The survey also highlighted a concerning sense of isolation among PVS sufferers, with many finding it challenging to receive assistance for basic tasks and feeling a lack of companionship.

In their quest for relief, these individuals have explored a variety of treatments, from oral steroids and gabapentin to lifestyle changes like intermittent fasting and reducing caffeine intake. But the random nature of these treatments highlights a glaring issue: the lack of scientifically supported therapies for PVS.

While we anticipate additional peer review of this preprint from Yale University School of Medicine, it's important to recognize that while PVS is uncommon, it remains a real issue for those experiencing it.

This is original content from NewsBreak’s Creator Program. Join today to publish and share your own content.

Comments / 25

Published by

MSc (Research) | Named Standford's world's top 1% scientists | Independent scientist | 10x first-author academic papers | 400+ articles on coronavirus


More from Shin

Comments / 0